Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Sino Biopharmaceutical's Revenue for the
six
months ended in Dec. 2025 was $2,025 Mil. Sino Biopharmaceutical's average Accounts Receivable for the
six
months ended in Dec. 2025 was $973 Mil.
Hence, Sino Biopharmaceutical's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.08.
Sino Biopharmaceutical (OTCPK:SBMFF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Sino Biopharmaceutical Receivables Turnover Related Terms
Sino Biopharmaceutical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a Receivables Turnover of 2.08 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sino Biopharmaceutical and its competitors. According to the industry distribution chart, Sino Biopharmaceutical ranks #420 out of 841 companies in the Biotechnology industry, placing it in the top 49.9%.
Is Sino Biopharmaceutical's Receivables Turnover too high?
Sino Biopharmaceutical's current Receivables Turnover is 2.08. The Biotechnology industry median Receivables Turnover is 5.28. Sino Biopharmaceutical's value of 2.08 is 60.6% below this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #420 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #420 out of 841 companies for Receivables Turnover. This puts Sino Biopharmaceutical in the upper half of its industry. The industry median Receivables Turnover is 5.28. Sino Biopharmaceutical's value of 2.08 is 60.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current Receivables Turnover of 2.08 is 60.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Sino Biopharmaceutical and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current Receivables Turnover is 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.59, compared to a current price of $0.64 — trading 8% above its estimated fair value. The current Receivables Turnover is 2.08 and 60.6% below the Biotechnology industry median of 5.28. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Receivables Turnover is 2.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of $0.64 is trading 8% above its estimated GF Value™ of $0.59.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
Receivables Turnover: 2.08
GF Value™: $0.59 vs. price of $0.64 (8% above fair value)
Industry Position: 60.6% below the Biotechnology median (#420 of 841)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score
Get the complete analysis for SBMFF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
